Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
New York, NY
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Huntersville, NC
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Huntersville, NC
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Portland, OR
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Houston, TX
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Ann Arbor, MI
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Detroit, MI
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Bronx, NY
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Dallas, TX
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
mi
from
Seoul,
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
mi
from
Seoul,
Click here to add this to my saved trials
The CHOICE Registry
The CHOICE Registry: A Research Initiative Examining Clinical, Economic, and Humanistic Outcomes in the Management of Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/26/2018
Ingalls Memorial Hospital
mi
from
Harvey, IL
The CHOICE Registry
The CHOICE Registry: A Research Initiative Examining Clinical, Economic, and Humanistic Outcomes in the Management of Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/26/2018
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer
Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Abrogate Oral Mucositis Induced by Combined Chemotherapy and Radiation in Head and Neck Cancer Patients
Status: Enrolling
Updated:  1/28/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer
Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Abrogate Oral Mucositis Induced by Combined Chemotherapy and Radiation in Head and Neck Cancer Patients
Status: Enrolling
Updated: 1/28/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Rocky Mountain Cancer Centers
mi
from
Denver, CO
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
New York Oncology Hematology
mi
from
New York, NY
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
New York Oncology Hematology
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Willamette Valley Cancer Institute and Research Center
mi
from
Springfield, OR
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Willamette Valley Cancer Institute and Research Center
mi
from
Springfield, OR
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Institute for Translational Oncology Research
mi
from
Greenville, SC
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Institute for Translational Oncology Research
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Evergreen Hematology & Oncology
mi
from
Spokane, WA
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Vancouver Cancer Center
mi
from
Vancouver, WA
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Vancouver Cancer Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Prostate Conformal Cryotherapy
Regional Cryoablation for Localized Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  1/29/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Prostate Conformal Cryotherapy
Regional Cryoablation for Localized Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 1/29/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations
Status: Enrolling
Updated:  1/29/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations
Status: Enrolling
Updated: 1/29/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations
Status: Enrolling
Updated:  1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations
Status: Enrolling
Updated: 1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
University of MD Greenbaum Cancer Center
mi
from
Baltimore, MD
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
University of MD Greenbaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Dana Farber Cancer Institute (DFCI)
mi
from
Boston, MA
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Dana Farber Cancer Institute (DFCI)
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Beth Israel Deaconess Medical Center (BIDMC)
mi
from
Boston, MA
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Beth Israel Deaconess Medical Center (BIDMC)
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Click here to add this to my saved trials
Can We Miss Pigmented Lesions in Psoriasis Patients?
Can We Miss Pigmented Lesions in Psoriasis Patients?
Status: Enrolling
Updated:  1/29/2018
UAB Dermatology
mi
from
Birmingham, AL
Can We Miss Pigmented Lesions in Psoriasis Patients?
Can We Miss Pigmented Lesions in Psoriasis Patients?
Status: Enrolling
Updated: 1/29/2018
UAB Dermatology
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  1/29/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 1/29/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  1/29/2018
Massacusetts General Hospital
mi
from
Boston, MA
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 1/29/2018
Massacusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  1/29/2018
Massachusetts General Hospital
mi
from
Boston, MA
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 1/29/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  1/29/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 1/29/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Mayo Clinic Arizona - Cancer Clinical Research Unit
mi
from
Scottsdale, AZ
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Mayo Clinic Arizona - Cancer Clinical Research Unit
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Stanford Cancer Center - Stanford University
mi
from
Stanford, CA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Stanford Cancer Center - Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine
mi
from
New York, NY
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Oregon Health and Science University
mi
from
Portland, OR
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
University of Virginia Health System
mi
from
Charlottesville, VA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
The Mayo Clinic
mi
from
Rochester, MN
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors
Estimating the Adherence Rate of a Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors
Status: Enrolling
Updated:  1/29/2018
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors
Estimating the Adherence Rate of a Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors
Status: Enrolling
Updated: 1/29/2018
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Biomarkers for Gynecologic Cancer
Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population
Status: Enrolling
Updated:  1/29/2018
Ohio State University
mi
from
Columbus, OH
Biomarkers for Gynecologic Cancer
Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population
Status: Enrolling
Updated: 1/29/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials